Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00331747
Status:
UNKNOWN
Last Update Posted:
2006-07-07
First Post:
2006-05-30
Brief Title:
Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate
Sponsor:
Sheba Medical Center
Organization:
Sheba Medical Center
Study Overview
Official Title:
Three Dimensional Gait Evaluation in Relapsing Remitting Multiple Sclerosis Patients Treated With Glatiramer Acetate
Status:
UNKNOWN
Status Verified Date:
2006-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Hypothesis Treatment with Glatiramer acetate prevents deterioration of gait in multiple sclerosis MS patients
During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment
During the study patients will undergo a 3 dimensional gait analysis before starting treatment with glatiramer acetate and after 1 year of treatment
Detailed Description:
Patients with a definite diagnosis of relapsing remitting multiple sclerosis MS will undergo a 3 dimensional gait analysis before initiation of treatment with glatiramer acetate The gait analysis will include kinematic evaluation using a Charnwood Dynamics CODA CX-1 system 4 AMTI force plates and a Noraxon telemetric EMG system Patients will be videotaped and will also undergo a detailed physical examination by a physical therapist
Treatment with Glatiramer acetate will be initiated after the gait analysis Therapy will be observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center
Repeat gait analysis will be performed after one year of treatment
Treatment with Glatiramer acetate will be initiated after the gait analysis Therapy will be observed and controlled by a neurologist fromn the staff of the Multiple Sclerosis Center
Repeat gait analysis will be performed after one year of treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None